SC Methylnaltrexone

DRUG3 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Advance Illness Patients With OICAdvanced Illness Patients With Opioid Induced ConstipationTerminal Illness

Phase 3

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

CompletedNCT00401362

Bausch Health Americas, Inc.Advanced Illness Patients With Opioid Induced Constipation

Start: 2003-02-28End: 2005-02-28Updated: 2019-11-25

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

CompletedNCT00402038

Bausch Health Americas, Inc.Advance Illness Patients With OIC

Start: 2004-02-29End: 2005-10-31Updated: 2019-11-25

Open-Label Treatment Extension of Protocol MNTX 302

CompletedNCT01367613

Bausch Health Americas, Inc.Terminal Illness

Start: 2004-03-31End: 2006-01-31Updated: 2019-11-27

Related Papers

Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness.

2023-10-201 citations

Subcutaneous Methylnaltrexone as Treatment for Opioid-Induced Constipation in Patients with Advanced Cancer and Noncancer Illnesses: A Post Hoc Analysis of Two Clinical Trials.

2023-02-101 citations

Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation.

2023-01-29

S165 Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

The American Journal of Gastroenterology2022-10-01

S187 A Pooled Analysis of the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Severe Medical Illness: The Impact of Baseline Opioid Equivalent Dose

The American Journal of Gastroenterology2021-10-01

Rescue-free laxation response with methylnaltrexone treatment in cancer patients with opioid-induced constipation: The impact of baseline ECOG status.

Journal of Clinical Oncology2021-05-20

The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation.

2021-03-314 citations

S0493 Subcutaneous Methylnaltrexone in Cancer and Non-Cancer Patients for Rapid Relief of Opioid-Induced Constipation

The American Journal of Gastroenterology2020-10-01

Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Advanced-Illness Patients With or Without Active Cancer

Pain Management2020-01-1712 citations

Efficacy variables in patients with cancer versus patients without cancer treated with methylnaltrexone or placebo: An analysis of two placebo-controlled studies.

Journal of Clinical Oncology2018-11-284 citations

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.

2016-08-2973 citations

Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials.

2014-05-1018 citations

Methylnaltrexone for opioid-induced constipation in advanced illness.

2008-05-01332 citations